Considerations for Clinical Trial Design and Data Analyses of Thorough QT Studies Using Drug-Drug Interaction

被引：11

作者：

Zhu, Hao ^{[1
]}

Wang, Yaning ^{[1
]}

Gobburu, Jogarao V. ^{[1
]}

Garnett, Christine E. ^{[1
]}

机构：

[1] US FDA, Div Pharmacometr, Off Clin Pharmacol, CDER, Silver Spring, MD 20993 USA

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 2010年 / 50卷 / 10期

关键词：

Concentration-QTc analysis; pharmacodynamic interaction; pharmacokinetic interaction; drug-drug interaction; metabolic enzyme inhibitor; KETOCONAZOLE;

D O I：

10.1177/0091270009358710

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1106 / 1111

页数：6

共 9 条

[1] MOLECULAR BASIS FOR DRUG ACTION [J].

ARIENS, EJ ;

SIMONIS, AM .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 1964, 16 (03) :137-&

[2]

ARIUENS E J, 1964, J Pharm Pharmacol, V16, P289

[3] Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects:: pharmacokinetic and pharmacodynamic effects [J].

Chaikin, P ;

Gillen, MS ;

Malik, M ;

Pentikis, H ;

Rhodes, GR ;

Roberts, DJ .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (03) :346-354

[4]

Dumaine R, 1998, J PHARMACOL EXP THER, V286, P727

[5]

FDA, 2006, GUID IND DRUG INT ST

[6]

Food and Drug Administration HHS, 2005, Fed Regist, V70, P61134

[7] The duration of systole in an electrocardiogram in normal humans and in patients with heart disease [J].

Fridericia, LS .

ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2003, 8 (04) :343-351

[8] Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug [J].

Mok, NS ;

Lo, YK ;

Tsui, PT ;

Lam, CW .

JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2005, 16 (12) :1375-1377

[9] Cardiac repolarisation and drug regulation - Assessing cardiac safety 10 years after the CPMP guidance [J].

Shah, Rashmi R. .

DRUG SAFETY, 2007, 30 (12) :1093-1110

← 1 →